Reviews/Ssris and Snris/SSRIs and SNRIs are effective first-line treatments in generalised anxiety disorder
· SS-ANX-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Four separate high-quality trials, each comparing a drug against a dummy pill in people with generalised anxiety disorder, found that three SSRIs ([1], [2], [6]) and one SNRI ([3]) all reduced anxiety more than placebo. The improvements were consistent in direction, and in two trials a clear majority of treated patients responded while fewer placebo patients did ([2], [6]). A small, uncontrolled study [16] separately showed anxiety falling during SSRI treatment, which adds only weak support. The word 'first-line' describes where a treatment sits relative to other options, and the trials here only test the drugs against placebo, not against other starting treatments. The trials were also short, running roughly eight to twelve weeks, so they say little about longer-term use. The panel therefore accepted that these drugs work in generalised anxiety disorder while being more cautious about the exact 'first-line' wording and about the single SNRI tested.
Four independent double-blind placebo-controlled RCTs each show a drug beating placebo on the primary Hamilton Anxiety outcome in GAD: escitalopram [1], sertraline [2], paroxetine [6] (SSRIs) and duloxetine [3] (an SNRI). Response rates favour active drug, with 63% versus 37% for sertraline [2] and 62% and 68% versus 46% for paroxetine [6]. The direction of effect is convergent across all four agents and both drug classes represented. An uncontrolled cohort [16] shows anxiety measures falling during SSRI treatment but has no placebo comparison and a cytokine primary endpoint, so it corroborates only weakly. The contested point: The evidence divides on wording and breadth rather than on whether the drugs work: the eligible trials establish placebo-controlled efficacy, not ranking as initial therapy, and every corpus item that actually asserts 'first-line' status was removed by the study-type filter. The SNRI class is represented by duloxetine [3] alone, so the plural 'SNRIs' is carried by a single agent.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
'First-line' is a guideline positioning term. The eligible primary RCTs establish placebo-controlled efficacy, not initial-therapy ranking against other options; every corpus item that actually asserts 'first-line' status was removed by the study-type filter, so the exact wording outruns the eligible evidence.
The SNRI class rests on a single agent (duloxetine, [3]); venlafaxine and SNRIs generally are not represented, so the plural 'SNRIs' is weakly carried.
Where it remains uncertain. The trials test efficacy against placebo, not 'first-line' ranking, and the SNRI arm rests on duloxetine [3] alone, with no maintenance data in the eligible corpus.
Aleatory
Cohort [16] enrols only 42 patients with no placebo arm, so its anxiety reduction is subject to chance and natural improvement.
Epistemic
Only duloxetine [3] represents the SNRI class; venlafaxine and other SNRIs are not tested in the eligible corpus, so 'SNRIs' as a class is unestablished.
Inferential
Placebo-controlled superiority is inferred to support 'first-line' standing, but ranking against other initial options is a different question the trials do not address.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
SSRI (escitalopram) efficacious vs placebo in a 681-patient GAD RCT.
“Escitalopram was efficacious in generalised anxiety disorder, 20 was not significantly superior to 10 mg/day.”
Panel auditInternal validity: high · scope of inference: Short-term efficacy of escitalopram (an SSRI) in adults with GAD; speaks to one SSRI, not SNRIs.Key limitations: 5 mg dose not separated from placebo on primary measure · more adverse-event withdrawals on escitalopram 20 mg and paroxetine · 12-week horizon only
SSRI (sertraline) response rate significantly exceeds placebo in GAD.
“The rate of responders, based on CGI improvement and last observation carried forward, was significantly higher for sertraline (63%) than placebo (37%).”
Panel auditInternal validity: high · scope of inference: Short-term (12-week) efficacy of sertraline (an SSRI) in adult outpatients with GAD.Key limitations: single SSRI · LOCF imputation · 12-week duration
SNRI (duloxetine) efficacious vs placebo in GAD — the sole eligible SNRI trial.
“Patients who received duloxetine treatment demonstrated significantly greater improvement in HAMA total scores (P=.02); a higher response rate (P=.03), and greater improvement (P=.04) than patients who received placebo.”
Panel auditInternal validity: high · scope of inference: Short-term efficacy of duloxetine (an SNRI) in adults with GAD.Key limitations: higher discontinuation for adverse events vs placebo · 10-week horizon · single SNRI
3 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Held below Established because, on the eligible primary corpus alone, the 'first-line' positioning is guideline-dependent (those sources were study-type excluded), the SNRI arm rests on one agent, and the trials are short-term.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
First-line ranking untested. The eligible trials show superiority to placebo, not standing relative to other initial treatments, which is what 'first-line' asserts. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Head-to-head RCTs comparing SSRIs/SNRIs against other candidate first-line options (e.g. CBT) in GAD with equivalence or ranking endpoints.
Open question: Do SSRIs and SNRIs rank as first-line therapy against other initial treatment options in GAD, rather than only beating placebo? Why it is still open: Every corpus item asserting first-line status was removed by the study-type filter, and the eligible trials are placebo-controlled only.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19